论文部分内容阅读
目的讨论曲美他嗪对陈旧心梗合并心衰患者CRP和心功能的影响。方法选择2011年2月-2011年2月治疗的陈旧心梗合并心衰患者120例,随机分成曲美他嗪组(n=60)和常规治疗组(n=60)。常规治疗组给予常规强心、利尿、扩血管、冠心病二级预防治疗;曲美他嗪组在上述治疗的基础上加用曲美他嗪,20mg/次,3次/日口服,连用3个月。结果曲美他嗪组心功能改善较常规治疗组显著提高。曲美他嗪组与常规治疗组血清CRP均有下降(P<0.01),曲美他嗪组治疗后下降程度较常规治疗组更明显(P<0.05)。治疗后两组左室射血分数值LVEF较治疗前亦均有改善(P<0.01),治疗后曲美他嗪组的改善程度较常规治疗组更明显(P<0.05)。结论曲美他嗪治疗陈旧心梗合并心衰患者疗效满意,能够降低CRP及改善心功能,值得临床关注。
Objective To investigate the effect of trimetazidine on CRP and cardiac function in elderly patients with myocardial infarction complicated with heart failure. Methods 120 elderly patients with heart failure and myocardial infarction who were treated from February 2011 to February 2011 were randomly divided into trimetazidine group (n = 60) and conventional treatment group (n = 60). Patients in the conventional treatment group were given secondary prevention and treatment of constipation, diuresis, vasodilation and coronary heart disease. Trimetazidine group was treated with trimetazidine 20mg once daily for 3 times a day for 3 months, Months. Results The improvement of cardiac function in trimetazidine group was significantly higher than that in the conventional treatment group. Serum CRP in trimetazidine group and conventional treatment group decreased (P <0.01), and decreased more in trimetazidine group than conventional treatment group (P <0.05). The left ventricular ejection fraction LVEF of both groups also improved after treatment (P <0.01), and the improvement of trimetazidine group was more obvious than that of conventional treatment group after treatment (P <0.05). Conclusion Trimetazidine treatment of elderly patients with heart failure myocardial infarction with satisfactory results, can reduce CRP and improve cardiac function, deserves clinical attention.